J. L. Sebastian

Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

J.A. Martínez‐Pin ̃eiro, N Flores, Santiago Isorna et al. · British Journal of Urology · 2002 · 217 citations · Full text

Medicine, Oncology, Urology +7

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin et al. · Nature Communications · 2022 · 81 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, Kaixing Le, Xin Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 35 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Safety of injectable autologous human fibroblasts

Gregory S. Keller, J. L. Sebastian, U. Lacombe et al. · Bulletin of Experimental Biology and Medicine · 2000 · 21 citations

Engineering, Bioengineering, Biomedical Engineering +9